

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

| | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | | x |
| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
| Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | x |
| Primary cultures: Provide species, strain, sex of origin, genetic modification status. | | x |
| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
| Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | x |
| Animal observed in or captured from the field: Provide species, sex and age where possible | | x |
| Model organisms: Provide Accession number in repository (where relevant) OR RRID | | x |
| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
| Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | | x |
| Microbes: provide species and strain, unique accession number if available, and source | | x |
| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Patients and control subjects were recruited prospectively and consented for this study under the auspices of IRB protocol # PRO15030072 issued through the University of Pittsburgh. | |
| Provide statement confirming informed consent obtained from study participants. | Patients were consented using a research consent separate from procedural consent. | |
| Report on age and sex for all study participants. | Participants >18y were recruited. Both sexes were recruited | |

Design

| | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | | x |
| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | x |
| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
| State whether and how the following have been done, or if they were not carried out. | | |
| Sample size determination | Samples from patients were collected sequentially (when possible). Based on differences between historical controls demonstrating large differences between certain mediators between the groups, we calculated that we would a minimum of 6 controls and 6 patients. This would give an alpha of 0.05 and power of 0.8 and is based from published mediator differences. We limited our N to the number of controls. | |
| Randomisation | No randomisation | |
| Blinding | Blinding occurred with Multiplex measurements and analysis | |
| Inclusion/exclusion criteria | Inclusion (patients): Age >18yrs, meeting clinical and anatomic criteria for endovenous ablation or sclerotherapy Exclusion (patients): cancer, active infection, active ulcer, peripheral arterial disease, kidney failure, CHF, active heart disease Inclusion (controls): Age >18 Exclusion (controls): no swelling, no varicose veins, no telangiectasias, no evidence of venous reflux. | |
| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
| State number of times the experiment was replicated in laboratory | | x |
| Define whether data describe technical or biological replicates | | x |
| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Patients and control subjects were recruited prospectively and consented for this study under the auspices of IRB protocol # PRO15030072 issued through the University of Pittsburgh. | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | x |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | | x |
| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a |
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | x |

Analysis

| Attrition | Yes (indicate where provided: section/paragraph) | n/a |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | | x |

| Statistics | Yes (indicate where provided: section/paragraph) | n/a |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Describe statistical tests used and justify choice of tests. | <p>Given very prominent differences seen between some mediators in prior work, our power calculation determined that we would need only 6 individuals per group to generate a potentially significant difference if seen. However, we aimed to recruit a minimum of 10 each. Given difficulties associated with recruiting controls we were able to recruit 8 and could not recruit more due to COVID 19. Mean values of inflammatory mediators, age and VCSS scores and their standard deviations were calculated. Individual inflammatory mediator data was compared between controls and subjects using Mann-Whitney U tests. Network analysis was carried out to define the central inflammatory network nodes in the control and CVI groups</p> <p>Connections were created if a correlation between two mediators was \geq to a specific threshold Pearson correlation, either 0.7 or 0.95 (equivalent to $p = 0.05$), as indicated. These cross-correlations were visualized as networks created with MATLAB[®] software (The MathWorks, Inc., Natick, MA). A robustness index was also calculated to measure network “strength”, by comparing the number of connections created with a Pearson correlation of 0.7 to one of 0.95.(15)</p> <p>Spearman’s correlation was performed to measure the strength of the association between IL-17A and GM-CSF and between IL-17A and IL-10 (Luminex™ data) using a modified version of a MATLAB[®]-based toolbox (26) as described previously (16). A p-value of less than 0.05 was considered significant.</p> | |

| Data Availability | Yes (indicate where provided: section/paragraph) | n/a |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| State whether newly created datasets are available, including protocols for access or restriction on access. | Data will be made available upon reasonable request | |
| If data are publicly available, provide accession number in repository or DOI or URL. | | x |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | | x |

| Code Availability | Yes (indicate where provided: section/paragraph) | n/a |
|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| For all newly generated code and software essential for replicating the main findings of the study: | | x |
| State whether the code or software is available. | | x |
| If code is publicly available, provide accession number in repository, or DOI or URL. | | x |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---------------------------------------------------------------------------------------|---------------------------------------------------------|------------|
| MDAR framework recommends adoption of discipline-specific guidelines, established and | | |

| | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|--|
| <p>endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.</p> | | |
| <p>State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.</p> | <p>ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.</p> | |

Article information: <https://dx.doi.org/10.21037/atm-21-688>